SYRE

SEC source: 0001636282-26-000100 · wk-form4_1785979922.xml · nonDerivative · entry 3

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,094

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.85 to $96.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001636282-26-000100 · wk-form4_1785979922.xml · nonDerivative · entry 2

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,394

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.84 to $95.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001636282-26-000100 · wk-form4_1785979922.xml · nonDerivative · entry 1

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,494

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

SEC source: 0001636282-26-000099 · wk-form4_1785979866.xml · nonDerivative · entry 5

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 567,540

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F7 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.46 to $97.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001636282-26-000099 · wk-form4_1785979866.xml · nonDerivative · entry 4

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 567,556

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.45 to $97.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001636282-26-000099 · wk-form4_1785979866.xml · nonDerivative · entry 3

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 568,948

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.45 to $96.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001636282-26-000099 · wk-form4_1785979866.xml · nonDerivative · entry 2

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 574,583

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.44 to $95.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001636282-26-000099 · wk-form4_1785979866.xml · nonDerivative · entry 1

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 581,740

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.42 to $94.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001636282-26-000087 · wk-form4_1783042377.xml · derivative · entry 4

Sloan Sheldon · CIK 0002038798 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 305,000

Underlying: Common Stock · 8,334 shares

Expires 2034-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F4 · derivative.exercise_date: This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001636282-26-000087 · wk-form4_1783042377.xml · nonDerivative · entry 3

Sloan Sheldon · CIK 0002038798 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001636282-26-000087 · wk-form4_1783042377.xml · nonDerivative · entry 2

Sloan Sheldon · CIK 0002038798 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,834

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001636282-26-000087 · wk-form4_1783042377.xml · nonDerivative · entry 1

Sloan Sheldon · CIK 0002038798 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,334

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

SEC source: 0001636282-26-000088 · wk-form4_1783042436.xml · derivative · entry 4

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 352,357

Underlying: Common Stock · 7,500 shares

Expires 2033-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

F5 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001636282-26-000088 · wk-form4_1783042436.xml · nonDerivative · entry 3

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,994

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.17 to $89.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · balance_after: Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001636282-26-000088 · wk-form4_1783042436.xml · nonDerivative · entry 2

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,719

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.13 to $88.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001636282-26-000088 · wk-form4_1783042436.xml · nonDerivative · entry 1

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,494

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

SEC source: 0001636282-26-000086 · wk-form4_1783042321.xml · nonDerivative · entry 3

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 582,540

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.86 to $88.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001636282-26-000086 · wk-form4_1783042321.xml · nonDerivative · entry 2

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 583,130

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.82 to $88.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001636282-26-000086 · wk-form4_1783042321.xml · nonDerivative · entry 1

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 587,364

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.82 to $87.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001853327-26-000008 · wk-form4_1782523902.xml · derivative · entry 4

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 359,857

Underlying: Common Stock · 15,000 shares

Expires 2033-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001853327-26-000008 · wk-form4_1782523902.xml · nonDerivative · entry 3

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,994

F1 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.78 to $87.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · balance_after: Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001853327-26-000008 · wk-form4_1782523902.xml · nonDerivative · entry 2

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,994

SEC source: 0001853327-26-000008 · wk-form4_1782523902.xml · nonDerivative · entry 1

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-26-076967 · tm2618664-2_4seq1.xml · derivative · entry 5

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 0

Underlying: Common Stock · 666,680 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-26-076967 · tm2618664-2_4seq1.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 0

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-26-076967 · tm2618664-2_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 4,684,781

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001636282-26-000084 · wk-form4_1782264740.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,606

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

SEC source: 0001636282-26-000078 · wk-form4_1780536719.xml · derivative · entry 3

Sloan Sheldon · CIK 0002038798 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 313,334

Underlying: Common Stock · 8,333 shares

Expires 2034-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F2 · derivative.exercise_date: This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001636282-26-000078 · wk-form4_1780536719.xml · nonDerivative · entry 2

Sloan Sheldon · CIK 0002038798 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

SEC source: 0001636282-26-000078 · wk-form4_1780536719.xml · nonDerivative · entry 1

Sloan Sheldon · CIK 0002038798 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

SEC source: 0001636282-26-000076 · wk-form4_1780536638.xml · derivative · entry 5

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 374,857

Underlying: Common Stock · 7,500 shares

Expires 2033-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

F6 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001636282-26-000076 · wk-form4_1780536638.xml · nonDerivative · entry 4

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,994

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.54 to $72.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · balance_after: Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001636282-26-000076 · wk-form4_1780536638.xml · nonDerivative · entry 3

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,094

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.38 to $71.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001636282-26-000076 · wk-form4_1780536638.xml · nonDerivative · entry 2

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,693

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.37 to $70.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001636282-26-000076 · wk-form4_1780536638.xml · nonDerivative · entry 1

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,494

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

SEC source: 0001636282-26-000077 · wk-form4_1780536669.xml · nonDerivative · entry 3

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 597,540

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.97 to $71.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001636282-26-000077 · wk-form4_1780536669.xml · nonDerivative · entry 2

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 600,834

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.96 to $70.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001636282-26-000077 · wk-form4_1780536669.xml · nonDerivative · entry 1

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 608,983

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.96 to $69.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001636282-26-000069 · wk-form4_1780091883.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Kiselak Tomas · CIK 0001830177 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Tomas Kiselak

Disclosed balance after: 8,026

Underlying: Common Stock · 8,026 shares

Expires 2036-05-27

F1 · derivative.exercise_date: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to Tomas Kiselak's continuous service to the Issuer through the applicable vesting date.

F2 · ownership.nature: Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.

SEC source: 0001636282-26-000068 · wk-form4_1780091789.xml · derivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,026

Underlying: Common Stock · 8,026 shares

Expires 2036-05-27

F1 · derivative.exercise_date: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

SEC source: 0001636282-26-000067 · wk-form4_1780091744.xml · derivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,026

Underlying: Common Stock · 8,026 shares

Expires 2036-05-27

F1 · derivative.exercise_date: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

SEC source: 0001636282-26-000066 · wk-form4_1780091721.xml · derivative · entry 1

Stelzer Laurie · CIK 0001644348 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,026

Underlying: Common Stock · 8,026 shares

Expires 2036-05-27

F1 · derivative.exercise_date: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

SEC source: 0001636282-26-000065 · wk-form4_1780091713.xml · derivative · entry 1

McKenna Mark C. · CIK 0001749623 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,026

Underlying: Common Stock · 8,026 shares

Expires 2036-05-27

F1 · derivative.exercise_date: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

SEC source: 0001859810-26-000002 · wk-form4_1780091687.xml · derivative · entry 1

Milligan Sandra · CIK 0001859810 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,026

Underlying: Common Stock · 8,026 shares

Expires 2036-05-27

F1 · derivative.exercise_date: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

SEC source: 0001636282-26-000053 · wk-form4_1778290306.xml · nonDerivative · entry 4

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,606

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.15 to $75.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001636282-26-000053 · wk-form4_1778290306.xml · nonDerivative · entry 3

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,875

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.15 to $75.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001636282-26-000053 · wk-form4_1778290306.xml · nonDerivative · entry 2

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 132,689

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.15 to $74.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001636282-26-000053 · wk-form4_1778290306.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 166,202

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.03 to $73.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0002038798-26-000004 · wk-form4_1777685676.xml · derivative · entry 9

Sloan Sheldon · CIK 0002038798 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 321,667

Underlying: Common Stock · 78,333 shares

Expires 2034-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

F8 · derivative.exercise_date: This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0002038798-26-000004 · wk-form4_1777685676.xml · nonDerivative · entry 8

Sloan Sheldon · CIK 0002038798 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.